

PERSONAL INFORMATION**Stefania Scala**

 Affiliation

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli
 Research department/Microenvironment Molecular Target Unit
 Via M. Semmola, 80131, Naples, Italy

 s.scala@istitutotumori.na.it

 <https://www.scopus.com/authid/detail.uri?authorId=7004629422>

Sex Female | *Nationality* Italian

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input type="checkbox"/> Full professor	<input type="checkbox"/> <input checked="" type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator
<input type="checkbox"/> Mid-Management Level	<input type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

WORK EXPERIENCE

August 2022 to date

Director Microenvironment Molecular Targets Unit

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli
 Research department/Microenvironment Molecular Target Unit
 Via M. Semmola, 80131, Naples, Italy

Main activities and responsibility: Assess, interpret and evaluate outcomes of research; Design and lead research programmes and projects; respond to tenders and calls for proposals, support and guidance to colleagues in order to improve the quality and impact of research, Contribute to the personal and professional development of the research team

Business or sector: Medical Research

May 2020 – August 2022

Acting Director Microenvironment Molecular Targets Unit

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli
 Research department/Microenvironment Molecular Target Unit
 Via M. Semmola, 80131, Naples, Italy

Main activities and responsibility: Design and lead research programmes and projects; respond to tenders and calls for proposals, support and guidance to colleagues in order to improve the quality and impact of research Contribute to the personal and professional development of the research team

Business or sector: Medical Research

December 2017 - April 2020

Group Leader Molecular Immunology and Immune-regulation

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli
 Research department/Functional Genomic Unit
 Via M. Semmola, 80131, Naples, Italy

Main activities and responsibility: Design and lead research programmes and projects; respond to tenders and calls for proposals, support and guidance to colleagues in order to improve the quality and impact of research Contribute to the personal and professional development of the research team

Business or sector: Medical Research

July 2014 – April 2020

Group Leader Functional Immunology

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli

Research department/Functional Genomic Unit

Via M. Semmola, 80131, Naples, Italy

Main activities and responsibility: Design and lead research programmes and projects; respond to tenders and calls for proposals, support and guidance to colleagues in order to improve the quality and impact of research Contribute to the personal and professional development of the research team

Business or sector: Medical Research

November 2002 – July 2014

Medical Oncologist

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli

Clinical Immunology

Via M. Semmola, 80131, Naples, Italy

Main activities and responsibility: Develop ideas for application of research outcomes Decide on research programmes and methodologies; Design and lead research programmes and projects; respond to tenders and calls for proposals; visit patients

Business or sector: Medical Research

November 2000 – October 2002

Senior Researcher

Biogen, Scarl

Via Camporeale 83031 Ariano Irpino (AV)

Main activities and responsibility: Assess, interpret and evaluate outcomes of research. Resolve problems of meeting research objectives and deadlines. Develop ideas for generating income and promoting research area. Develop ideas for application of research outcomes Decide on research programmes and methodologies

Business or sector: Medical Research

August 1990 – November 1995

Fellow

National Institute of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA

Medicine Branch, National Cancer Institute, National Institute of Health

Main activities and responsibility: Assess, interpret and evaluate outcomes of research. Resolve problems of meeting research objectives and deadlines. Develop ideas for generating income and promoting research area. Develop ideas for application of research outcomes Decide on research programmes and methodologies

Business or sector: Medical Research

EDUCATION AND TRAINING

1996 - 2000

PhD in Cellular and Molecular Biology and Pathology

Università degli Studi di Napoli "Federico II", Naples, Italy

Oncology, Cellular and Molecular Pathology, Biology

1988 - 1991

Oncology Specialty

Università degli Studi di Napoli "Federico II", Naples, Italy

Oncology

1982 - 1988

Medical Degree, MD

Università degli Studi di Napoli "Federico II", Naples, Italy

WORK ACTIVITIES

Awards	1990-1994 General Fellow, Medicine Branch, NHI NCI, Bethesda, MD 1994-1995 Fogarty Fellow Medicine Branch, NHI NCI, Bethesda, MD 1999-2002 Senior Researcher Biogem, Ariano Irpino, (AV) Board Full Professor in Patologia Generale e Patologia Clinica- 06/A2-ASN 2016 Board Full Professor in Malattie del Sangue, Oncologia e Reumatologia 06/D3-ASN2016
Editorial activity	Associated Editor for "Clinical Cancer Research" Reviewer for: Clinical Cancer Research, Cancer Immunology and Immunotherapy, Molecular Cancer Therapeutics, Cell Death and Differentiation, Scientific Report, Oncogene, Melanoma Research, Journal of Cellular and Molecular Medicine, Molecular Carcinogenesis, ACS Publication, The Journal of Immunotherapy of Cancer, Science Signaling
Invited presentations	1. 2.
Grants	<ul style="list-style-type: none">• Italian Ministry of Health - 2023-2025 - From diagnostic to theranostic CXCR4-targeting PET probe. Proof of concept in Non Small Cell Lung Cancer (NSCLC)-PDX model. PNRR-POC-2022-12376329. Importo finanziato: 1.000.000€• AIRC - 2021-2025 - New generation of CXCR4 antagonists: Peptide R54 from biomolecular mechanisms to first in man clinical study (IG-24746). Importo finanziato: 589.000€ (Deliberazione del Direttore Generale n. 1018 del 08/10/2021)• ERANET EURONANOMED - 2020-2022 - Development of CXCR4 targeting-nanosystem-probes for molecular imaging of cancer cells and tumor microenvironment (NAN-4-TUM). Importo finanziato: 1.059.091€ di cui 250.000€ per l'unità INT-IRCCS Pascale• Italian Ministry of Health - 2020-2022 - Preclinical and Clinical Development of a 68Ga-NOTA-AHX-R54, a CXCR4-PET tracer targeting tumoral and stromal cells in human solid cancers. First in Man Clinical Trial (RF-2018-12367026) Importo finanziato: 450.000€ di cui 300.000€ per INT-IRCCS Pascale (Deliberazione del Direttore Generale n. 883 del 11/09/2020).• ERANET TRANSCAN - 2017-2020 - pREdiction of niVOLUmab acTION in metastatic renal cancer patients: Treg function, tumoral access and NK interactions as predictive biomarkers of immunotherapy. Importo finanziato: 745.000€ di cui 385.000€ per l'unità INT-IRCCS Pascale (Deliberazione del Direttore Generale n. 368 del 17/05/2017)• ERANET EURONANOMED - 2015-2017 - "(Nano) system with active targeting to sensitive colorectal cancer stem cells antitumoral treatment". Importo finanziato: 1.032.106 € di cui 250.000€ per l'unità INT-IRCCS Pascale• Intramural-Italian Ministry of Health - 2014-2015 - Approccio integrato per la caratterizzazione prognostica-predittiva del microambiente tumorale nel cancro renale. Importo finanziato: 30.000€/anno (Delibera 311 del 29.03.2013, Delibera 659 del 20/08/2018)• AIRC - 2012-2015 - Preclinical and clinical development of a novel class of ligand-based CXCR4-inhibitor cyclic peptides (IG13192). Importo finanziato: 248.000€ (Deliberazione del Direttore Generale n. 1033/2014).• AIRC - 2009-2012 - Microenvironment in dissemination and drug sensitivity of kidney cancer: role of CXCR4-CXCR7-CXCL12 (IG9032). Importo finanziato: 180.000€ (Deliberazioni del Direttore Generale n. 56/2010, n. 98/2011 e n. 144/2012)• Alliance Against Cancer (Alleanza Contro il Cancro) ACC - 2006-2011 - Chemokine and Chemokine Receptors as molecular and biological markers of clinical response and therapeutic target• AIRC - 2005-2008 - Role of CXCR4 in melanoma: a possible prognostic factor and a target of therapy (IG1107).
Patents	<ul style="list-style-type: none">• "CYCLIC PEPTIDES BINDING CXCR4 RECEPTOR AND RELATIVE MEDICAL AND DIAGNOSTIC USES" EP2528936B9, WO 2011/092575• "RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS" WO2021130329

ADDITIONAL INFORMATION

Publications	Total number of publications in peer-review journals: 142 Total number of citations: 5349 H index (Scopus): 4
---------------------	---

